Track topics on Twitter Track topics that are important to you
Spark Therapeutics has submitted a marketing authorization application to the European Medicines Agency for Luxturna, its one-time gene therapy for the treatment of vision loss, according to a company press release.Luxturna, the proposed trade name for voretigene neparvovec, would treat vision loss caused by biallelic RPE65 gene mutations in Leber congenital amaurosis or retinitis pigmentosa, the release said.
Original Article: Marketing authorization application for Luxturna filedNEXT ARTICLE
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
Congenital conditions are those which are present from birth. They include structural deformities or loss of function in organs such as the <!--LGfEGNT2Lhm-->heart, gut or skeletal system. They can be corrected by <!--LGfEGNT2Lhm-->surgery, m...